CD19 and autoimmune hepatitis: In agreement with the results of these earlier experiments, αGalCer/CD1d-NP therapy suppressed both necroinflammation and fibrosis in hFTCD-induced AIH in both NOD mice as well as CD19-Cre-negative NOD.B2m–/–/B2mloxP mice (Fig. 7g).